Delving into the Latest Updates on IHA-24 with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide

Synonyms

Target

hemagglutinin

Action

inhibitors

Mechanism

hemagglutinin inhibitors(Influenza virus hemagglutinin glycoproteins inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza, HumanPneumonia

Inactive Indication-

Originator Organization

Tokyo Metropolitan Institute of Medical Science

Active Organization

Tokyo Metropolitan Institute of Medical Science

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Sanada, Takahiro ; Kawaoka, Yoshihiro ; Ishigaki, Hirohito ; Shichinohe, Shintaro ; Saito, Makoto ; Yamane, Daisuke ; Sakoda, Yoshihiro ; Ikejiri, Ai ; Tsukiyama-Kohara, Kyoko ; Ogasawara, Kazumasa ; Nakayama, Misako ; Ozawa, Makoto ; Ito, Risa ; Honda, Tomoko ; Kida, Hiroshi ; Yamamoto, Naoki ; Munakata, Tsubasa ; Le, Thi Quynh Mai ; Kohara, Michinori ; Itoh, Yasushi ; Suga, Hiroaki ; Yamaji, Kenzaburo ; Yasui, Fumihiko ; Katoh, Takayuki

AbstractMost anti-influenza drugs currently used, such as oseltamivir and zanamivir, inhibit the enzymatic activity of neuraminidase. However, neuraminidase inhibitor-resistant viruses have already been identified from various influenza virus isolates. Here, we report the development of a class of macrocyclic peptides that bind the influenza viral envelope protein hemagglutinin, named iHA. Of 28 iHAs examined, iHA-24 and iHA-100 have inhibitory effects on the in vitro replication of a wide range of Group 1 influenza viruses. In particular, iHA-100 bifunctionally inhibits hemagglutinin-mediated adsorption and membrane fusion through binding to the stalk domain of hemagglutinin. Moreover, iHA-100 shows powerful efficacy in inhibiting the growth of highly pathogenic influenza viruses and preventing severe pneumonia at later stages of infection in mouse and non-human primate cynomolgus macaque models. This study shows the potential for developing cyclic peptides that can be produced more efficiently than antibodies and have multiple functions as next-generation, mid-sized biomolecules.

100 Deals associated with IHA-24

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Preclinical	Japan	Tokyo Metropolitan Institute of Medical Science	11 May 2021
Pneumonia	Preclinical	Japan	Tokyo Metropolitan Institute of Medical Science	11 May 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data